Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,669.96
(
-0.69%
)
US TECH 100
23,988.80
(
-0.60%
)
Dow Jones
46,569.50
(
-0.90%
)
Brent Oil
105.72
(
5.04%
)
Bitcoin
71,210.99
(
-3.69%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 28
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: DewDiligence post# 162066

Tuesday, 06/04/2013 4:04:37 AM

Tuesday, June 04, 2013 4:04:37 AM

Post# of 257253

Quiz (low difficulty): Why did SNY take a writeoff for the failure of Iniparib (#msg-88593358) but not for the failure of Otamixaban (#msg-88592744)?

Because Sanofi got Iniparib through the 2009 purchase of BiPar Sciences Inc., while Otamixaban was discovered and developed in-house.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today